Investing in
Life Sciences

We drive bold smart solutions to extend longevity

  • About DKLS
  • Mission
  • Goal
  • Specialisation
  • Investment principles
Deep Knowledge Life Sciences is a new type of smart investment fund focusing on disruptive technologies in Biotech, Pharmaceuticals, Medical Devices and Healthcare industries in order to solve the most critical challengies faced by humankind in these fields
Our mission is to drive bold smart solutions to extend longevity
We are here to be a global leader in Medicine and Biotechnologies, setting new standards for human and social good
We invest in breakthrough technologies with a primary focus on anti-aging and personalized medicine.

  • Genetics and Personalized Medicine

  • Anti – Aging and Oncology

  • Precision Medicine

  • Human Biotechology

  • We invest in disruptive technologies, transforming old and creating new exponential industries in Life Science

  • We invest in teams and technologies at early stages

  • We invest up to $20M in a single round

Portfolio


Nonprofit


Pathway Pharmaceuticals


Pathway Pharmaceuticals ­ is a Hong Kong­ based personalized medicine company with a primary focus on oncology. The company provides solutions that help to make more informed decisions for cancer therapies selection for individual patients. The company’s core project is OncoFinder - a clinical decision-making support system, which uses Big Data bioinformatics, molecular analysis, and genetics to provide a complete analysis of a patient’s cancer to offer the most efficient personalized treatment.


Visit site

OncoFinder


OncoFinder is a system of personalized chemotherapy selection for people with cancer, based on the analysis of transcriptome data and intracellular signaling pathways of the patient. The system increases the effectiveness of chemotherapy assigned by the formula selection according to the individual characteristics of the patient's tumor, which reduces the toxic side effects of treatment.


Visit site

Beauty.AI


First International Beauty Contest Judged by Artificial Intelligence


Visit site

Aging.AI


This is a deep-learned predictor of your age made with a deep neural network trained on hundreds of thousands anonymized human blood tests. Enter your data below and Aging.ai will guess your age and… gender


Visit site

RYNKL


We applied Deep Learning technologies to recognize the intensity of your wrinkles and learned how to track the minute changes that occur during aging. We then developed a mobile app, which takes your picture, consider biomarkers of your face ageing and gives you objective picture of how your youthfulness changes in result of treatment.


Visit site

VITAL


VITAL (Validating Investment Tool for Advancing Life Sciences) enables us to screen hundreds of start-ups, private and public companies in the life science sector by evaluating market sizes, technology potential and company prospects.


Visit site

Insilico Medicine Inc.


Insilico Medicine Inc. is a bioinformatics company in the field of antiaging and personalized medicine. The company is committed to extension of human longevity by developing diseases and aging biomarkers, geroprotectors, and new tools for aging research using best practices from academia and IT. Insilico Medicine is an expert in drug repurposing, pathway activation analysis and deep learning tools and provides services to pharmaceutical, cosmetics, nutraceutical and personalized medicine companies.


Visit site

Pharma.AI


Pharma.AI is a deep learning knowledge management system. Pharma.AI utilizes the latest advances in deep learning to improve computer analysis of massive multi-omics data and millions of tissue-specific pathway activation profiles obtained using proprietary methods developed by the company.


Visit site

Canada Cancer and Aging Research Laboratories



Canada Cancer and Aging Research Laboratories (CCARL) is a research and development company offering a personalized approach to cancer treatment. The company provides decision making systems in oncology based on knowledge of molecular signatures of various cancers, sex- and age-specificity of cancer response to treatment, and molecular and biochemical characteristics of regulation of various pro- and anti-cancer pathways.


Visit site

Atlas Regeneration


Atlas Regeneration Inc. is a company dedicated to developing novel software platforms and algorithms for drug discovery relating to regenerative medicine and stem cell research.


Visit site

Vision Genomics


Vision Genomics is a biotechnology-based company that focuses on research and development of therapeutics for age-related eye diseases. Our company undertakes an interdisciplinary approach using big data analysis to produce working solutions for age-related eye diseases.


Visit site

The Biogerontology Research Foundation


The Biogerontology Research Foundation (the BGRF) is a UK-based charity organization. The objective of research conducted or funded by the BGRF is to produce effective cures or treatments for the diseases and frailty commonly associated with ageing in the human population. The foundation constantly makes open educational forums and supports the publication of scientific articles.


Visit site

Super Centenarians


An international initiative aimed at challenging people to live longer. SuperCentenarians includes longevity advice and a $1 million prize to the first person to reach 123 years of age.


Visit site

GLI


The Global Longevity Initiative aims to extend the period of healthy longevity to 100 years and beyond. The initiative is an international partnership of world leading universities, governmental agencies, biotech and pharmaceutical companies in order to create the science, technology, and commercialization hubs in the field of preventative and personalized medicine all around the globe.


Almost Human


Coming soon


BioViva Inc


Bioviva USA Inc is a cell and gene therapy company committed to extending human health-spans and providing regenerative medicine to the masses.

BioViva is the first company in the world to treat a person with gene therapy to reverse biological aging, using a combination of two therapies. Testing and research on these therapies is continuing in BioViva’s affiliated labs worldwide.


Visit site

Dmitry Kaminskiy

Founder and Senior Partner

Biotech AI - VITAL

AI for Investment Decision-Making

Charlotte Casebourne

Associate Director

Scientific advisory board

Alex Zhavoronkov

Physics and Mathematics PhD

Avi Roy

Biomedical Science PhD

Richard Barker

Biomedical Science PhD

Dmitry Kaminskiy

Founder and Senior Partner

Dmitry Kaminskiy is a new generation enterpreneur and well-known visionary originally from Eastern Europe. He has been concentrating on developing his business in East Asia as a priority in recent years. Dmitry built his wealth on IT-solutions, analytics and predictions for private banking, financial engineering and rapidly growing industries. He is known for his experience in information technology, advanced computer science and the development of advanced Big Data industrial expert analytics systems. He has a wide network spanning scientific and business commiunities across the globe.

Biotech AI - VITAL

AI for Investment Decision-Making

The Validating Investment Tool for Advancing Life sciences is a virtual smart machine which deals with forecasting and investment analysis in the biotechnology industry. VITAL makes its decisions by scanning prospective companies’ financing, clinical trials, intellectual property, and previous funding rounds. At the moment, it is the most powerful robotized expert system in the biotechnology industry.

Alex Zhavoronkov

Physics and Mathematics PhD

Alex Zhavoronkov, PhD is an international adjunct professor at the Moscow Institute of Physics and Technology. He is the CEO and co-founder of InSilico Medicine, Inc., a Baltimore-based company utilizing Big Data analysis for aging research and drug discovery. Dr. Zhavoronkov is the author of multiple peer-reviewed scientific as well as popular papers and books on the many aspects of biogerontology, aging research, and aging economics including “The Ageless Generation: how biomedical advances will transform the global economy” published by Palgrave Macmillan. He holds a PhD in physics and mathematics from the Moscow State University.

Avi Roy

Biomedical Science PhD

Avi Roy - is a Regenerative Medicine specialist, and a top level scientific advisor to politicians, and industrialist from around the world. Avi is the President of the Oxford based Biogerontology Research Foundation an anti-aging think tank. Avi is an biomedical scientist and the co-founder of the Exponential Technologies Institute, a next-generation hub for technology and knowledge creation. He is a Research Fellow at the Institute for Translational Medicine at the University of Buckingham (BITM), and at the Centre for Advancing Sustainable Medical Innovation (CASMI) at the University of Oxford. Avi recently became a Partner at Deep Knowledge Life Sciences UK, which is focused on investments in biotech, medtech, and longevity. Avi frequently speaks at elite global conferences, and writes in the biggest news publications including The Guardian.

Richard Barker

Biomedical Science PhD

Richard's doctoral research involved biological applications of MRT as well as postdoctoral studies in Munich, Germany and Leeds, UK. Today, Professor Richard Barker is an Executive Director and former of the Centre for the Advancement of Sustainable Medical Innovation (CASMI) - a partnership between Oxford University and UCL, which is created to develop new structures for medical innovation. Within his past leaderships roles including head of McKinsey'd European healthcare practice, General Manager of Healthcare Solutions for IBM and Chief Executive of Chiron Diagnostics. Furthemore, Richard was a co-founder of Life Sciences UK, a member of the NHS Stakeholder Forum, and vice-chair of the UK Clinical Trials Collaboration. Richard’s 25-year business career has spanned biopharmaceuticals, diagnostics and medical informatics. Richard’s book on the future of healthcare: ‘2030 – The Future of Medicine: Avoiding a Medical Meltdown’, is published by Oxford University Press. He speaks frequently on the future of the life sciences, new medical technology and the restructuring of our healthcare systems.

Charlotte Casebourne

Associate Director

Charlotte is dedicated to driving innovation in healthcare biotechnology to enable solutions to the highest-impact medical challenges.
  • New press-release
  • 2016
  • 2015
  • 2014
  • VIDEO

July 07, 2016

BIOVIVA, GENE THERAPY AND BLOCKCHAIN MERGES IN RUSSIA

During June 20th to the 23rd, founder and CEO of BioViva USA Inc, Elizabeth Parrish visited Moscow at the invitation of board member of the Blockchain Community and founder of Future Fintech accelerator, Alex Fork. As a result of the meeting an announcement was made with BioViva to open an outreach office in Russia. Additionally, an agreement to implement a crowd investing campaign for BioViva using the Waves Blockchain platform was made.
For the first time in history two of the fastest growing trends – Longevity and BlockChain – are coming together.

As part of her visit to Moscow, Elizabeth Parrish participated in a number of activities: June 20th, at the Intercontinental Hotel, a press conference where Elizabeth Parrish founder of BioViva, Avi Roy a representative of the Global Healthspan Policy Institute, President of Biogerontology Research Foundation (Oxford), and Sasha Ivanov, founder of Waves blockchain platform participated. At this conference they announced plans for BioViva to issue shares on the blockchain basis. On June 20th, Elizabeth Parrish presented her company with Avi Roy at a scientific medical conference at the Agency of Strategic Initiatives, at the invitation of Daria Khaltourina, chairwoman of the Public Health and Demography Problems Council, as well as a board member of International Longevity Alliance. The representatives of the National Technology Initiative, HealthNet Project and the representatives of the Russian Longevity Community were present at this meeting. The conference discussed several issues including the possibility of the use of advanced methods for the treatment of aging and the prevention of diseases, prospects for partnership with major Russian companies, academic and government institutions, prospects and challenges in biomedical innovation start-ups, issues of state regulation of biomedicine and in particular, anti-aging treatments; including prospects of Russia joining the list of countries with an innovative health system.

On June 21st, Digital October hosted a popular science conference titled “Model of World, Elizabeth Parrish: Editing Longevity Genes”, which was attended by over 300 people. During the event, Elizabeth answered a series of questions such as: How do genes work? How are you checking the results? What does this mean for the future of humans? Are we on the threshold of a new round of evolution? and many others.

Elizabeth also participated in a number of TV programs and interviews on several Russian TV channels. BioViva USA Inc. is a company that has ambitious plans to create therapies that help people achieve healthy longevity, and to one day have this technology affordably available for all people. Alex Fork invited Sasha Ivanov, founder of the blockchain project, Waves Platform, to support a more dynamic development of BioViva’s project in Russia and worldwide. For this purpose it was decided to issue shares on the basis of Blockchain technology. Elizabeth Parrish found support for BioViva from Blockchain.Community and Waves Blockchain Platform, a joint activity will help accelerate the achievement of the set goals, using advanced financial technologies.

Elizabeth Parrish: – “BioViva will become the first biotech company to issue shares on the base of BlockChain technology. The partnership of BioViva and Waves is an important statement. This approach it is not about the amount of attracted investments, instead it is a prescient example of implementation. Our joint success will create a positive example for other biotech companies and will have beneficial impact on the future development of the whole Longevity Industry. ”

Reference Information:
Elizabeth Parrish – the first woman to successfully use gene therapy to slow aging. She is the founder and director of the company BioViva USA Inc, who has the ambitious plans to make the healthy longevity technology available to all. Elizabeth is a humanitarian, and entrepreneur and and an innovator. She is the leading person commercializing the field of genetic research, and she has launched a new era of self-experimentation and developed a new business model for medical procedures. She is the lead newsmaker for the medical business community and for those who follow healthy lifestyle. Her activities are reflected in major media publications around the world.

Avi Roy – is a regenerative medicine specialist, a scientific consultant for politicians and influential members financial and industrial world. He is the president of the Oxford Research Fund Biogerontology (Biogerontology Research Foundation). He is one of the founders of the organization Global Healthspan Policy Institute which brings together the world’s leading universities, government agencies, biotech and pharmaceutical companies. These organizations collectively aim to extend healthy longevity up to 100 years or more. Avi is also a partner in the biotech investment fund Deep Knowledge Life Sciences (DKLS) UK. which is focused on investments in biotech, medtech, and longevity. Avi is a frequent speaker at international conferences, publishes articles in the world’s major media outlets, including The Guardian.

Alex Fork – representative of Deep Knowledge Life Sciences in Russia, founder of fintech cluster Future Funtech (Futurefintech.org – community in Russia, helping to develop companies in the field of novel financial technologies). Member of the Board of Blockchain.Community (the largest association of Russian BlockChein entrepreneurs). Member of the working groups and speaker of the conferences: the National Payment Council, the Central Bank of the Russian Federation, the National Bank of Belarus, the National Bank of Moldova. Author of the book “Bitcoin. More than the money.”

Sasha Ivanov – Sasha Ivanov is the founder and CEO of the WAVES project. Sasha started with programming robots for Forex trading a few years ago, using a model of artificial neural network and ideas borrowed from his academic past. He was always fascinated by the infinite possibilities of neural networks, as well as closely following the new Internet payment system, which inspired him to create the development and exchange services. Sasha also created Cryptoasset.Fund, blockchain oriented technology venture fund. Sasha Ivanov founded the Waves project at the beginning of 2016, and in May 2016 has attracted an investment of $ 16 million for the development of his project. Waves Blockchain platform allows you to create digital stock at a minimum cost, quickly and efficiently, taking into account existing legislation. This financial instrument is expanding investment opportunities, now including healthy longevity technologies field, making them accessible to all, blurring the boundaries between countries and continents.



Send your proposals to info@deepknowledge.life or use the form bellow

Press release
BIOVIVA, GENE THERAPY AND BLOCKCHAIN MERGES IN RUSSIA
CEO of BioViva USA Inc, Elizabeth Parrish visited Moscow at the invitation of board member of the Blockchain Community, Alex Fork.
July 07, 2016

Read more >